General AML,   IDH1/2

Julie Bergeron | EHA 2018 | What are the latest emerging novel approaches for treatment in AML?

L: English
Watch French version

At the 2018 European Hematology Association Meeting, Julie Bergeron from Hospital Maisonneuve-Rosemont, Quebec, CA, talks about the latest emerging agents for therapy in acute myeloid leukemia including BCL2 inhibitors such as venetoclax and also IDH inhibitors.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF